0001104659-26-056658
SEC filingArmata Pharmaceuticals announced FDA Fast Track Designation for AP-SA02, a phage candidate for S. aureus bacteremia, potentially accelerating development and review.
Armata Pharmaceuticals received FDA Fast Track Designation for AP-SA02, its intravenously administered multi-phage product candidate for adjunct treatment of complicated Staphylococcus aureus bacteremia (SAB) caused by MSSA or MRSA. This designation facilitates more frequent FDA engagement, rolling BLA review, and potential Accelerated Approval and Priority Review. The company plans to initiate a Phase 3 superiority study in the second half of 2026. The designation highlights the serious nature of SAB and the need for new treatments, supporting Armata's phage platform. CEO Dr. Deborah Birx emphasized the milestone and the potential to improve upon current standard of care. The press release was furnished as Exhibit 99.1 and not deemed filed for SEC purposes.